We also propose that the interruption of the TRIB1-FAK-Src-MMP-2 and/or TRIB1-ERK-MMP-2 pathways might be a novel therapeutic method for controlling CRC metastasis. The gene discussed is MMP2; the disease is colorectal carcinoma.